Sanofi Expands Dren Bio Partnership with $1.7B Autoimmune Collaboration
核心洞察
Sanofi has entered a new strategic collaboration with Dren Bio (搜索) worth up to $1.7 billion to develop next-generation B-cell depleting therapies for autoimmune diseases (搜索).
The partnership builds on Sanofi's earlier $600 million acquisition of Dren Bio (搜索)'s DR-0201 program, now called SAR448501 (搜索), which is currently in Phase I trials.
Dren Bio (搜索) will receive $100 million upfront and leverage its Targeted Myeloid Engager and Phagocytosis Platform to discover multispecific antibody therapeutics.
Sanofi has significantly expanded its partnership with Dren Bio (搜索) through a new strategic collaboration worth up to $1.7 billion to develop next-generation B-cell depleting therapies for autoimmune diseases (搜索). The agreement builds on the pharmaceutical giant's earlier acquisition of Dren Bio's lead program and represents a major commitment to advancing innovative immunology treatments.
Building on Previous Success
The new collaboration follows Sanofi's acquisition of Dren Bio (搜索)'s DR-0201 program earlier this year for $600 million upfront, plus $1.3 billion in development and launch milestone payments. The acquired program, now designated SAR448501 (搜索), is a CD20 bispecific monoclonal antibody (搜索) currently being evaluated in two Phase I trials for undisclosed inflammatory indications (搜索).
According to the companies, SAR448501 (搜索) has demonstrated robust B-cell depletion with the potential to induce sustained treatment-free remission in patients with autoimmune diseases (搜索). This early success has prompted Sanofi to deepen its relationship with Dren Bio (搜索) through the expanded partnership.
Leveraging Proprietary Platform Technology
The new agreement will harness Dren Bio (搜索)'s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class multispecific antibody therapeutics. Under the collaboration terms, Dren Bio will receive an upfront payment of $100 million and remain eligible for up to $1.7 billion in development, regulatory, and commercial milestone payments.
"Our newly expanded strategic alliance with Dren Bio (搜索) reflects Sanofi's deep commitment to developing best-in-class therapies with the potential to achieve remission in patients with immune-mediated diseases (搜索)," said Alyssa Johnsen, Global Therapeutic Head, Immunology and Oncology Development at Sanofi. "By combining Dren Bio's unique scientific approach with Sanofi's development expertise, we aim to accelerate the development of innovative therapies for patients in need."
Strategic Development Structure
The collaboration follows a structured approach where both companies will work together on discovery and preclinical development activities. Following development candidate selection, Sanofi will assume responsibility for subsequent development, manufacturing, regulatory, and commercialization efforts.
Notably, Dren Bio (搜索) retains the option to enter into a U.S. profit/loss sharing arrangement with Sanofi. If exercised, Dren Bio will co-fund 40% of ongoing global development costs in exchange for U.S. co-promotion rights and a 50/50 share of U.S. profits and losses. The company will also remain eligible to receive milestones and tiered royalties on net sales outside the United States.
Industry Implications
Amit Mehta, Ph.D., Chief Operating Officer and Chief Business Officer of Dren Bio (搜索), emphasized the significance of the expanded partnership: "Sanofi has been a valued partner in unlocking the full potential of deep B-cell depletion through the acquisition of DR-0201, and we're thrilled to expand our collaboration by further leveraging the capabilities of our Targeted Myeloid Engager and Phagocytosis platform. The U.S. profit/loss share option allows us to partner with a global commercial leader and represents an important milestone in our growth into a fully integrated biopharmaceutical company."
The collaboration positions both companies to advance innovative approaches to treating autoimmune diseases (搜索), with the potential to develop therapies that could achieve sustained remission for patients with immune-mediated conditions.